Skip to results

Area of interest

Area of interest

Type (1 selected)

Type

Guidance programme

Showing 51 to 75 of 315

Guidance and quality standards awaiting development
TitleType
Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]Technology appraisal guidance
Caval valve implantation for tricuspid regurgitationInterventional procedures guidance
Cenobamate for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy TS ID 10214Technology appraisal guidance
Concizumab for preventing bleeding episodes in haemophilia A or haemophilia B [ID5099]Technology appraisal guidance
Corticosteroid-releasing bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitisInterventional procedures guidance
Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source (ID1417)Technology appraisal guidance
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 TS ID 11839Technology appraisal guidance
Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over TS ID 11838Technology appraisal guidance
Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]Technology appraisal guidance
Daratumumab in combination for untreated multiple myeloma when high-dose chemotherapy and autologous stem cell transplant are suitable ID6249Technology appraisal guidance
Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer TSID 12045Technology appraisal guidance
Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]Technology appraisal guidance
Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy TS ID 11840Technology appraisal guidance
Delgocitinib for treating moderate to severe chronic hand eczema ID6408Technology appraisal guidance
Depemokimab for treating chronic rhinosinusitis with nasal polyps ID 6449Technology appraisal guidance
Depemokimab for treating severe eosinophilic asthma in people 12 years and over TSID 12017Technology appraisal guidance
Dersimelagon for treating erythropoietic protoporphyria and X-linked protoporphyria in people 12 years and over TS ID 10392Technology appraisal guidance
Deucravacitinib for treating active psoriatic arthritis TS ID 11981Technology appraisal guidance
Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery ID1154Technology appraisal guidance
Digital front door for people accessing NHS Talking TherapiesDiagnostics guidance
Digital platforms for community based self-management of mild to moderate osteoarthritis and joint painMedical technologies guidance
Digital platforms to support cardiac rehabilitationMedical technologies guidance
Dostarlimab with carboplatin and paclitaxel for untreated recurrent or advanced endometrial cancer with high microsatellite stability or mismatch repair proficiency ID6415Technology appraisal guidance
Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]Technology appraisal guidance
Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA963) [ID6426]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All